Literature DB >> 20583295

First missense mutation in the SOST gene causing sclerosteosis by loss of sclerostin function.

Elke Piters1, Cavit Culha, Martiene Moester, Rutger Van Bezooijen, Dirk Adriaensen, Thomas Mueller, Stella Weidauer, Karen Jennes, Fenna de Freitas, Clemens Löwik, Jean-Pierre Timmermans, Wim Van Hul, Socrates Papapoulos.   

Abstract

Sclerosteosis is a rare bone dysplasia characterized by greatly increased bone mass, especially of the long bones and the skull. Patients are tall, show facial asymmetry and often have syndactyly. Clinical complications are due to entrapment of cranial nerves. The disease is thought to be due to loss-of-function mutations in the SOST gene. The SOST gene product, sclerostin, is secreted by osteocytes and transported to the bone surface where it inhibits osteoblastic bone formation by antagonizing Wnt signaling. In a small Turkish family with sclerosteosis, we identified a missense mutation (c.499T>C; p.Cys167Arg) in exon 2 of the SOST gene. This type of mutation has not been previously reported and using different functional approaches, we show that it has a devastating effect on the biological function of sclerostin. The affected cysteine is the last cysteine residue of the cystine-knot motif and loss of this residue leads to retention of the mutant protein in the ER, possibly as a consequence of impaired folding. Together with a significant reduced ability to bind to LRP5 and inhibit Wnt signaling, the p.Cys167Arg mutation leads to a complete loss of function of sclerostin and thus to the characteristic sclerosteosis phenotype. (c) 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20583295     DOI: 10.1002/humu.21274

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  18 in total

Review 1.  A Comprehensive Overview of Skeletal Phenotypes Associated with Alterations in Wnt/β-catenin Signaling in Humans and Mice.

Authors:  Kevin A Maupin; Casey J Droscha; Bart O Williams
Journal:  Bone Res       Date:  2013-03-29       Impact factor: 13.567

Review 2.  Wnt signaling and the control of human stem cell fate.

Authors:  J K Van Camp; S Beckers; D Zegers; W Van Hul
Journal:  Stem Cell Rev Rep       Date:  2014-04       Impact factor: 5.739

Review 3.  MANAGEMENT OF ENDOCRINE DISEASE: Novel anabolic treatments for osteoporosis.

Authors:  Ernesto Canalis
Journal:  Eur J Endocrinol       Date:  2017-11-07       Impact factor: 6.664

Review 4.  Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches.

Authors:  Ernesto Canalis
Journal:  Nat Rev Endocrinol       Date:  2013-08-13       Impact factor: 43.330

5.  Mutations in LRP5 cause primary osteoporosis without features of OI by reducing Wnt signaling activity.

Authors:  Johanna Korvala; Harald Jüppner; Outi Mäkitie; Etienne Sochett; Dirk Schnabel; Stefano Mora; Cynthia F Bartels; Matthew L Warman; Donald Deraska; William G Cole; Heini Hartikka; Leena Ala-Kokko; Minna Männikkö
Journal:  BMC Med Genet       Date:  2012-04-10       Impact factor: 2.103

6.  Myeloma cells suppress osteoblasts through sclerostin secretion.

Authors:  S Colucci; G Brunetti; A Oranger; G Mori; F Sardone; G Specchia; E Rinaldi; P Curci; V Liso; G Passeri; A Zallone; R Rizzi; M Grano
Journal:  Blood Cancer J       Date:  2011-06-24       Impact factor: 11.037

7.  DNA methylation regulates sclerostin (SOST) expression in osteoarthritic chondrocytes by bone morphogenetic protein 2 (BMP-2) induced changes in Smads binding affinity to the CpG region of SOST promoter.

Authors:  Ioanna Papathanasiou; Fotini Kostopoulou; Konstantinos N Malizos; Aspasia Tsezou
Journal:  Arthritis Res Ther       Date:  2015-06-12       Impact factor: 5.156

8.  A Novel Loss-of-Sclerostin Function Mutation in a First Egyptian Family with Sclerosteosis.

Authors:  Alaaeldin Fayez; Mona Aglan; Nora Esmaiel; Taher El Zanaty; Mohamed Abdel Kader; Mona El Ruby
Journal:  Biomed Res Int       Date:  2015-04-23       Impact factor: 3.411

9.  Mutational analysis of sclerostin shows importance of the flexible loop and the cystine-knot for Wnt-signaling inhibition.

Authors:  Verena Boschert; Maarten van Dinther; Stella Weidauer; Katharina van Pee; Eva-Maria Muth; Peter Ten Dijke; Thomas D Mueller
Journal:  PLoS One       Date:  2013-11-29       Impact factor: 3.240

Review 10.  Role of the Wnt/β-Catenin Pathway in Renal Osteodystrophy.

Authors:  Sarah-Kim Bisson; Roth-Visal Ung; Fabrice Mac-Way
Journal:  Int J Endocrinol       Date:  2018-04-02       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.